Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 54

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice

Snow, R.J, Turnbull, J, da Silva, S, Jiang, F, Tarnopolsky, M.A·2003·Neuroscience
DOI 10.1016/s0306-4522(03)00212-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0306-4522(03)00212-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 40

  1. Andreassen, 2001, Increases in cortical glutamate concentrations in transgenic amytrophic lateral sclerosis mice are attenuated by creatine supplementation, J Neurochem, 77, 383, 10.1046/j.1471-4159.2001.00188.x · DOI
  2. Bensimon, 1994, ALS/riluzole study group, N Engl J Med, 330, 585, 10.1056/NEJM199403033300901 · DOI · Paper page
  3. Cookson, 1999, Oxidative stress and motor neurone disease, Brain Path, 9, 165, 10.1111/j.1750-3639.1999.tb00217.x · DOI
  4. Cudkowicz, 2002, Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity, Neurology, 59, 729, 10.1212/WNL.59.5.729 · DOI
  5. Dandapani, 2002, Estrogen-astrocyte interactions, BMC Neurosci, 3, 1, 10.1186/1471-2202-3-1 · DOI · Paper page
  6. Dengler, 1999, Current treatment pathways in ALS, Neurology, 53, S4
  7. Derave, 2002, Metabolic and contractile properties in skeletal muscles of a transgenic mouse model of amyotrophic lateral sclerosis, J Physiol, 539P, 46P
  8. Dolder, 2001, Mitochondrial creatine kinase in contact sites, Biol Signals Recept, 10, 93, 10.1159/000046878 · DOI
  9. Dugan, 1997, Carboxyfullerenes as neuroprotective agents, Proc Natl Acad Sci USA, 94, 9434, 10.1073/pnas.94.17.9434 · DOI · Paper page
  10. Ferrante, 1997, Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis, Neurochemistry, 69, 2064, 10.1046/j.1471-4159.1997.69052064.x · DOI · Paper page
  11. Fitch, 1961, The metabolism of creatine-1-C14 by mice with hereditary muscular dystrophy, J Clin Invest, 40, 850, 10.1172/JCI104319 · DOI
  12. Gurney, 1997, The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies, J Neurol Sci, 152, S67, 10.1016/S0022-510X(97)00247-5 · DOI
  13. Gurney, 1996, Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis, Ann Neurol, 39, 147, 10.1002/ana.410390203 · DOI · Paper page
  14. Gurney, 1994, Motor neuron degeneration of mice that express a human Cu, Zn superoxide dismutase mutation, Science, 264, 1772, 10.1126/science.8209258 · DOI · Paper page
  15. Harris, 1974, Glycogen, glycolytic intermediates and high-energy phosphates determined in biopsy samples of musculus quadriceps femoris of man at rest, Scand J Clin Lab Invest, 33, 109, 10.3109/00365517409082477 · DOI · Paper page
  16. Hottinger, 1997, The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis, Eur J Neurosci, 9, 1548, 10.1111/j.1460-9568.1997.tb01511.x · DOI
  17. Hugon, 1996, Riluzole and ALS therapy, Wien Med Wochenscher, 146, 185
  18. Ikeda, 2000, Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse, ALS, 1, 207, 10.1080/14660820050515205 · DOI
  19. Jiang, 2001, Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice, J Neurol Sci, 180, 52, 10.1016/S0022-510X(00)00421-4 · DOI
  20. Kennel, 2000, Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuropathy (pmn), J Neurol Sci, 180, 55, 10.1016/S0022-510X(00)00423-8 · DOI
  21. Klivenyi, 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat Med, 5, 347, 10.1038/6568 · DOI · Paper page
  22. Lacomblez, 1996, ALS/Riluzole study group, Lancet, 347, 1425, 10.1016/S0140-6736(96)91680-3 · DOI · Paper page
  23. Martin, 1993, The neuroprotective agent rilozule inhibits release of glutamate and aspartate from slices of hippocampal area CA1, Eur J Pharmacol, 250, 473, 10.1016/0014-2999(93)90037-I · DOI · Paper page
  24. Matthews, 1998, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease, J Neurosci, 18, 156, 10.1523/JNEUROSCI.18-01-00156.1998 · DOI · Paper page
  25. Mazzini, 2001, Effects of creatine supplementation on exercise performance and muscular strength in amytrophic lateral sclerosis, J Neurol Sci, 191, 139, 10.1016/S0022-510X(01)00611-6 · DOI
  26. McKenna, 1999, Creatine supplementation increases skeletal muscle creatine content, but not maximal intermittent intense exercise performance in humans, J Appl Physiol, 87, 2244, 10.1152/jappl.1999.87.6.2244 · DOI · Paper page
  27. Noh, 2000, A novel neuroprotective mechanism of riluzole, Neurobiol Dis, 7, 375, 10.1006/nbdi.2000.0297 · DOI
  28. O'Gorman, 1997, The role of creatine kinase inhibition of mitochondrial permeability transition, FEBS Lett, 414, 253, 10.1016/S0014-5793(97)01045-4 · DOI · Paper page
  29. Pulido, 1998, Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells, FEBS Lett, 439, 357, 10.1016/S0014-5793(98)01399-4 · DOI
  30. Rosen, 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amytrophic lateral sclerosis, Nature, 362, 59, 10.1038/362059a0 · DOI · Paper page
  31. Rothstein, 1995, Excitotoxic mechanisms in the pathogenesis of amytrophic lateral sclerosis, Adv Neurol, 68, 7
  32. Singer, 1996, Estrogen protects primary cortical neurons from glutamate toxicity, Neurosci Lett, 212, 13, 10.1016/0304-3940(96)12760-9 · DOI · Paper page
  33. Tarnopolsky, 2001, Creatine transporter and mitochondrial creatine kinase protein content in myopathies, Muscle Nerve, 24, 682, 10.1002/mus.1055 · DOI · Paper page
  34. Trieu, 1999, Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke, Biochem Biophys Res Commun, 258, 685, 10.1006/bbrc.1999.0577 · DOI
  35. Vielhaber, 2001, Effect of creatine supplementation on metabolite levels in ALS motor cortices, Exp Neurol, 172, 377, 10.1006/exnr.2001.7797 · DOI
  36. Wallimann, 1992, Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands, Biochem J, 281, 21, 10.1042/bj2810021 · DOI · Paper page
  37. Wendt, 2002, Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice, Free Rad Biol Med, 32, 920, 10.1016/S0891-5849(02)00784-0 · DOI
  38. White, 1996, Mitochondrial depolarization in glutamate-stimulated neurons, J Neurosci, 16, 5688, 10.1523/JNEUROSCI.16-18-05688.1996 · DOI · Paper page
  39. Wise, 2002, Estrogen and neuroprotection, Trends Endocrinol Metab, 13, 229, 10.1016/S1043-2760(02)00611-2 · DOI
  40. Xu, 1996, Phosphocreatine-dependent glutamate uptake by synaptic vesicles, J Biol Chem, 271, 13435, 10.1074/jbc.271.23.13435 · DOI

Cited by

Metadata

Authors
Snow, R. J., Turnbull, J., da Silva, S., Jiang, F., & Tarnopolsky, M. A.
Venue
Neuroscience
Publisher
Elsevier BV
Published
2003-07
Volume
119
Issue
3
Pages
661-667
ISSN
0306-4522
DOI
10.1016/s0306-4522(03)00212-4
Cited by
54
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.